Managing Side Effects of Angiogenesis Inhibitors in Renal Cell Carcinoma

Publisher： Karger

E-ISSN： 2296-5262|30|10|519-524

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.30, Iss.10, 2007-09, pp. : 519-524

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR inhibitors in renal cell carcinoma

By Battelli Chiara   Cho Daniel C  

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 359-367

Future Medicine

Access to resources Recommend Favorite

Stable Disease in Renal Cell Carcinoma After Using Signal Transduction Inhibitors

By  

Reviews on Recent Clinical Trials, Vol. 5, Iss. 2, 2010-05 ,pp. : 117-122

Bentham Science Publishers

Access to resources Recommend Favorite

Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 4, 2013-04 ,pp. : 345-351

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)

By  

Current Signal Transduction Therapy, Vol. 8, Iss. 3, 2013-12 ,pp. : 219-228

Bentham Science Publishers

Access to resources Recommend Favorite

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma

By  

Current Signal Transduction Therapy, Vol. 8, Iss. 3, 2013-01 ,pp. : 210-218

Bentham Science Publishers

Access to resources Recommend Favorite